#SABCS24: Olema makes case for its oral SERD with fresh data cut from Phase 1b/2 breast cancer trial

Olema Oncology unveiled new data from a Phase 1b/2 breast cancer trial on Tuesday, as it strives to catch up with other companies with oral selective estrogen receptor degraders (SERDs). Olema’s vision is to co ...